

---

## CONTENTS

### ENVIRONMENTAL HEALTH CRITERIA ON PRINCIPLES AND METHODS FOR ASSESSING AUTOIMMUNITY ASSOCIATED WITH EXPOSURE TO CHEMICALS

PREAMBLE	xi
ACRONYMS AND ABBREVIATIONS	xxii
1. SUMMARY	1
2. INTRODUCTION AND DEFINITIONS OF AUTOIMMUNITY AND AUTOIMMUNE DISEASE	5
3. INTRODUCTION TO THE IMMUNE SYSTEM: FOCUS ON AUTOIMMUNE MECHANISMS	9
3.1 Introduction	9
3.2 The innate immune response	10
3.3 The adaptive immune response	11
3.3.1 Function	11
3.3.2 Aberrant function	14
3.3.3 Ageing	15
3.4 Mechanisms of self-tolerance	16
3.5 Immunopathogenesis of autoimmune disease	18
3.5.1 Mechanisms of induction	18
3.5.2 Effector mechanisms	21
3.6 Summary	22
4. INTRINSIC FACTORS IN AUTOIMMUNITY	24
4.1 Genetic factors involved in the induction of or susceptibility for autoimmune diseases	24
4.1.1 Probable monogenic autoimmune syndromes	24
4.1.2 Multigenic autoimmune diseases	26
4.1.2.1 Immune deficiencies	27

4.1.2.2	Defects and dysregulation in apoptosis pathways and cell cycle regulation	29
4.1.2.3	Associations with MHC alleles or haplotypes	31
4.1.2.4	Polymorphisms in genes coding for regulatory and effector molecules of the immune system	35
4.1.2.5	Hormones and genes	37
4.1.2.6	Genetic polymorphisms of xenobiotic-metabolizing enzymes	38
4.1.2.7	Genes coding for autoantigens	39
4.1.2.8	Genes coding for enzymes involved in post-translational modification of autoantigens	40
4.1.2.9	DNA methylation	41
4.1.3	Problems and perspectives	41
4.2	Hormonal influence on autoimmunity	42
4.2.1	Pregnancy	42
4.2.1.1	Suppression of autoimmunity	42
4.2.1.2	Stimulation of autoimmunity	43
4.2.2	Psychological stress	46
5.	CLINICAL EXPRESSION OF HUMAN AUTOIMMUNE DISEASES	47
5.1	Introduction	47
5.2	Addison disease	50
5.3	ANCA-associated vasculitis	51
5.4	Antiphospholipid syndrome	52
5.5	Coeliac disease	53
5.6	Diabetes mellitus	54
5.7	Goodpasture disease	55
5.8	Guillain-Barré syndrome	56
5.9	Autoimmune haemolytic anaemia	57
5.9.1	Warm autoimmune haemolytic anaemia	57
5.9.2	Cold autoimmune haemolytic anaemia	58
5.9.3	Drug-induced autoimmune haemolytic anaemia	59
5.10	Autoimmune hepatitis	59
5.11	Inflammatory bowel disease	61
5.11.1	Crohn disease	61

5.11.2	Ulcerative colitis	62
5.12	Multiple sclerosis	63
5.13	Myasthenia gravis	64
5.14	Myocarditis	66
5.15	Autoimmune myositis	66
5.16	Paraneoplastic neurological syndromes	67
5.17	Pemphigus/pemphigoid	68
5.17.1	Pemphigus	69
5.17.2	Pemphigoid	70
5.18	Pernicious anaemia	70
5.19	Autoimmune polyglandular syndromes	71
5.19.1	APGS type 1	71
5.19.2	APGS type 2	72
5.19.3	APGS type 3	72
5.20	Primary biliary cirrhosis	72
5.21	Psoriasis	73
5.22	Rheumatoid arthritis	74
5.23	Scleroderma (systemic sclerosis)	75
5.24	Sjögren syndrome	77
5.25	Systemic lupus erythematosus and lupus syndrome	78
5.25.1	Systemic lupus erythematosus	78
5.25.2	Lupus syndrome	79
5.26	Autoimmune thrombocytopenia	80
5.26.1	Immune thrombocytopenic purpura	80
5.26.2	Thrombotic thrombocytopenic purpura	81
5.26.3	Drug-induced thrombocytopenia	81
5.27	Autoimmune thyroid diseases	82
5.27.1	Graves disease	83
5.27.2	Hashimoto thyroiditis	83
5.27.3	Iodine and thyroid disease	84
5.28	Diseases with autoimmune components	85
6.	EPIDEMIOLOGY	87
6.1	Descriptive epidemiology	87
6.1.1	Demographic patterns	89
6.1.2	Co-morbidity of autoimmune diseases	91
6.2	Epidemiology of autoantibodies	92
6.2.1	Prevalence of autoantibodies in the general population	92

6.2.2	Associations between antibodies and environmental exposures	94
7.	MECHANISMS OF CHEMICAL-ASSOCIATED AUTOIMMUNE RESPONSES	96
7.1	General	96
7.2	Induction of antigen-specific responses	98
7.2.1	Formation of neoantigens	98
7.2.2	Cross-reactivity	99
7.2.3	Release of non-tolerant epitopes	100
7.2.4	Interference with central tolerance	101
7.2.5	Signal 2 increasing mechanisms	102
7.2.5.1	Importance of signal 2	102
7.2.5.2	Induction of signal 2	103
7.2.6	Immunoregulation	104
7.3	Other mechanisms	106
8.	CHEMICAL/PHYSICAL AGENTS AND AUTOIMMUNITY	107
8.1	Toxic oil syndrome	107
8.1.1	Clinical features of toxic oil syndrome	108
8.1.2	Immune markers in toxic oil syndrome	109
8.1.3	Experimental studies of toxic oil syndrome	111
8.2	TCDD (dioxins)	114
8.3	Pesticides	115
8.3.1	General	115
8.3.2	Hexachlorobenzene	117
8.3.2.1	Accidental poisoning in Turkey	118
8.3.2.2	Adverse immune effects of hexachlorobenzene	118
8.4	Ultraviolet radiation	122
8.5	Silica	122
8.5.1	Introduction to epidemiological studies of silica exposure	122
8.5.2	Occupational silica exposure and systemic autoimmune diseases	124
8.5.3	Experimental studies of immune- and autoimmune-related effects of silica	127
8.5.4	Summary	130
8.6	Heavy metals	131

---

8.6.1	Mercury	131
8.6.2	Gold	135
8.6.3	Cadmium	135
8.6.4	Other heavy metals	136
8.7	Solvents	138
8.8	Tobacco smoke	141
8.9	Ethanol	145
8.10	Iodine	148
8.11	Therapeutic agents	149
8.11.1	General	149
8.11.2	Hydralazine	150
8.11.3	Procainamide	151
8.11.4	D-Penicillamine	152
8.11.5	Zimeldine	153
8.11.6	Gold drugs	153
8.11.7	Biopharmaceuticals	155
8.11.8	Diethylstilbestrol	156
8.11.8.1	Diethylstilbestrol-induced immune alterations	156
8.11.8.2	Immune effects of diethylstilbestrol in humans	157
8.11.8.3	Conclusion	159
8.12	Silicones	159
8.12.1	Introduction	159
8.12.2	Silicone breast implants and systemic disease	160
8.12.3	Conclusion	162
9.	NON-CHEMICAL FACTORS IN AUTOIMMUNITY	163
9.1	Infections: cause of autoimmunity, and immune programming	163
9.1.1	Streptococcus and rheumatic fever	165
9.1.2	Hepatitis C virus	166
9.1.3	Epstein-Barr virus	167
9.1.4	Other infections	167
9.1.5	Absence of infections: the hygiene hypothesis	168
9.2	Vaccine-related factors	169
9.2.1	Vaccines themselves	169
9.2.2	Vaccine additives	170
9.3	Dietary factors	171
9.3.1	Caloric restriction and leptin	172

9.3.2	Dietary fat and fatty acid content	172
9.3.3	Antioxidants	174
9.3.4	Vitamin D	174
9.3.5	L-Tryptophan and eosinophilia myalgia syndrome	175
10.	ANIMAL MODELS TO ASSESS CHEMICAL-INDUCED AUTOIMMUNITY	178
10.1	Introduction	178
10.2	Rat models	180
10.2.1	The Brown Norway rat model	180
10.2.1.1	Metals	181
10.2.1.2	D-Penicillamine	182
10.2.1.3	Hexachlorobenzene	182
10.2.2	Other rat models	183
10.3	Mouse models	183
10.3.1	Metals	184
10.3.2	Drugs	184
10.3.3	Pristane	185
10.4	Genetically predisposed animal models	186
10.4.1	Systemic lupus erythematosus-prone strains of mice	186
10.5	Other species	187
10.6	Local and popliteal lymph node assays	188
10.6.1	Introduction	188
10.6.2	Primary, secondary, and adoptive popliteal lymph node assays and the lymph node proliferation assay	188
10.6.3	Reporter antigen popliteal lymph node assay	189
10.6.4	Popliteal lymph node assay as predictive assay	191
10.7	Testing strategy	191
11.	HUMAN TESTING FOR AUTOIMMUNE DISEASE	193
11.1	Introduction	193
11.2	Methods of human autoantibody detection	195
11.2.1	Indirect immunofluorescence technique	195
11.2.2	Counter-immunoelectrophoresis	195
11.2.3	Haemagglutination	196

11.2.4 Enzyme-linked immunosorbent assay/ fluorescent enzyme immunoassay	197
11.2.5 Radioimmunoassay	198
11.2.6 Immunoblotting	199
11.2.7 Multiplex analysis	199
11.3 Selection of detection method	200
11.3.1 Autoantigens	200
11.3.2 Anti-immunoglobulin reagents	202
11.4 Clinical interpretation	203
11.5 Human immunoglobulins	204
11.5.1 Autoimmune disease and human immunoglobulin levels	204
11.5.2 Quantification of human immunoglobulins	205
11.6 Testing in the diagnosis of delayed-type chemical hypersensitivity	207
11.7 Conclusions	208
 12. RISK ASSESSMENT	 211
12.1 Introduction	211
12.2 Hazard identification of chemical-induced autoimmune disease (animal models)	212
12.3 Exposure assessment (animal models)	213
12.4 Mode of action	213
12.5 Epidemiological issues	215
12.6 Susceptibility factors	216
12.7 Burden of autoimmune disease	217
 13. CONCLUSIONS AND RECOMMENDATIONS	 219
13.1 Conclusions	219
13.2 Recommendations	220
 TERMINOLOGY	 222
 REFERENCES	 256
 RESUME	 325
 RESUMEN	 330